{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:59:17Z","timestamp":1792760357231,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijgc.2025.101988","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:23:22Z","timestamp":1750879402000},"page":"101988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-2534","authenticated-orcid":false,"given":"Victoria M.","family":"Ettorre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-2819","authenticated-orcid":false,"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1016-7851","authenticated-orcid":false,"given":"Na","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-334X","authenticated-orcid":false,"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-3338","authenticated-orcid":false,"given":"Namrata","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Max Philipp","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-3300","authenticated-orcid":false,"given":"Luca","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.101988_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101988_bib2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/diagnostics12020458","article-title":"Low-grade serous carcinoma of the ovary: the current status","volume":"12","author":"Babaier","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"10324","key":"10.1016\/j.ijgc.2025.101988_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101988_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/iep.12174","article-title":"Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma","volume":"97","author":"Xu","year":"2016","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.ijgc.2025.101988_bib5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijgc.2025.101988_bib6","series-title":"FDA Grants Regular Approval to Sacituzumab Govitecan for Triple-Negative Breast Cancer","year":"2021"},{"issue":"29","key":"10.1016\/j.ijgc.2025.101988_bib7","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101988_bib8","article-title":"Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer","volume":"54","author":"Greenman","year":"2024","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101988_bib9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2019.11.018","article-title":"In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma","volume":"156","author":"Han","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101988_bib10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","article-title":"Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients","volume":"46","author":"Bignotti","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2025.101988_bib11","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e195","article-title":"The life and times of low-grade serous carcinoma of the ovary","volume":"33","author":"Gershenson","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10200","key":"10.1016\/j.ijgc.2025.101988_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25011089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25011089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:14:27Z","timestamp":1788232467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25011089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1048891X25011089"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101988","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101988"}}